Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 2012. The report serves as a notification to the market regarding the company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a capital structure notification rather than a financial performance report.
Material Changes
The filing details the company's issued share capital as of November 30, 2012:
- Total Issued Ordinary Shares: 5,399,665,851 (25p each)
- Treasury Shares: 490,140,427
- Total Voting Rights: 4,909,525,424
No material changes to financial performance or operational status are reported in this specific filing.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to statutory disclosure of share capital and voting rights.
Investor Verification Checklist
- Verify the total number of voting rights (4,909,525,424) for compliance with disclosure thresholds.
- Confirm the number of treasury shares held (490,140,427) as of November 30, 2012.
- Review the company's Form 20-F for comprehensive financial performance data not included in this 6-K.